{
    "root": "304cd284-e513-7821-e063-6394a90a0d35",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Cyclobenzaprine Hydrochloride",
    "value": "20250314",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "CYCLOBENZAPRINE HYDROCHLORIDE",
            "code": "0VE05JYS2P"
        }
    ],
    "indications": "Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. \n  \n                       Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. \n  \n                     \n                     Cyclobenzaprine hydrochloride tablets, USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted.\n                     \n                       Cyclobenzaprine hydrochloride tablets, USP have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy.",
    "contraindications": "For most patients, the recommended dose of cyclobenzaprine hydrochloride tablets is 5 mg three times a day. Based on individual patient response, the dose may be increased to 10 mg three times a day.  Use of cyclobenzaprine hydrochloride tablets for periods longer than two or three weeks is not recommended. (see\n \n  \n                        \n                           INDICATIONS AND USAGE\n                        \n                     ). \n  \n                       Less frequent dosing should be considered for hepatically impaired or elderly patients (see\n \n  \n                        \n                           PRECAUTIONS, Impaired Hepatic Function\n                        \n                     \n                     ,and\n \n  \n                        \n                           Use in the Elderly\n                        \n                     ).",
    "warningsAndPrecautions": "Cyclobenzaprine Hydrochloride Tablets USP, 10 mg are butterscotch yellow, biconvex, 5-sided D-shaped film-coated tablets, debossed with ‘D’ and ‘32’ on one side and plain on other side.\n                  \n                  \n                  NDC: 70518-3764-00\n                  NDC: 70518-3764-01\n                  NDC: 70518-3764-02\n                  PACKAGING: 12 in 1 BOTTLE PLASTIC\n                  PACKAGING: 14 in 1 BOTTLE PLASTIC\n                  PACKAGING: 21 in 1 BOTTLE PLASTIC \n                  \n                  \n                  \n                  \n                  STORAGE\n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].\n                  \n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Hypersensitivity to any component of this product. \n  \n                       Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. Hyperpyretic crisis seizures, and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitor drugs. \n  \n                       Acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure. \n  \n                       Hyperthyroidism."
}